– Oral Presentation of complete data from the three-year
MATCH Phase 2 trial
– Poster Presentation demonstrating preclinical proof of
concept of safety and efficacy of RTX001, an autologous engineered
macrophage cell therapy for end stage liver disease
EDINBURGH, Scotland and LONDON, Oct. 1, 2024
Resolution Therapeutics Limited ("Resolution" or "Company"), a
clinical-stage biopharmaceutical company focused on unlocking the
regenerative potential of macrophage therapy for the treatment of
inflammatory and fibrotic diseases, today announces two
abstracts have been selected for presentations at the American
Association for the Study of Liver Disease (AASLD) The Liver
Meeting® 2024. The conference will take place in San Diego, California, between 15-19 November 2024.
Professor Stuart Forbes, founder
of Resolution, Professor of Transplantation and Regenerative
Medicine at the University of Edinburgh
and Consultant Hepatologist at the Edinburgh Royal Infirmary, will
give an oral presentation of the complete three-year data from the
MATCH Phase 2 trial of autologous macrophage therapy in compensated
cirrhosis. Lara Campana, Ph.D.,
co-founder and Vice President of Research Operations at Resolution
will present a poster detailing the preclinical proof of concept of
safety and efficacy for RTX001, a novel autologous engineered
macrophage cell therapy for end-stage liver disease.
Oral Presentation Details:
Title: Autologous macrophage therapy decreases major
clinical outcomes in patients with compensated cirrhosis: extended
data from a randomized controlled Phase 2 trial
Publication Number: 95
Author: Stuart J. Forbes, MB CHB, FRCP(Ed), PhD
Date/Time: Monday 18 November 2024, 5:00pm – 6:30pm
PDT
Poster Presentation Details:
Title: Preclinical proof of concept of safety and
efficacy for RTX001, a novel autologous macrophage cell therapy
product for end-stage liver disease
Publication Number: 3556
Author: Lara Campana,
Ph.D.
Date/Time: Sunday 17 November 2024, 8:00am – 5:00pm
PDT
Members of the Resolution senior leadership team will attend the
conference. Please reach out to set up a meeting to learn more
about the Company.
NOTES TO EDITORS
About Resolution Therapeutics
Resolution Therapeutics is a clinical-stage biopharmaceutical
company focused on unlocking the regenerative potential of
macrophage therapy for the treatment of inflammatory and fibrotic
diseases. The Company leverages its proprietary cell
characterization and engineering platform to develop autologous
macrophages with distinct pro-regenerative properties for superior
patient outcomes across the spectrum of inflammatory and fibrotic
diseases. Resolution's initial focus is on developing RTX001, its
lead product candidate with first-in-class potential supported by
preclinical data demonstrating anti-fibrotic and anti-inflammatory
advantages relative to non-engineered macrophages, for patients
diagnosed with end-stage liver disease. The Company is also
advancing efforts to expand the potential of its platform into
indications beyond liver disease where engineered macrophages have
therapeutic potential. Resolution, a spinout from Professor
Stuart Forbes's lab at the
University of Edinburgh, is based in
Edinburgh and London. Learn more by visiting
https://resolution-tx.com/ and engage with us on LinkedIn.
About AASLD
AASLD is the leading organization of scientists and health care
professionals committed to preventing and curing liver disease. It
fosters research that leads to improved treatment options for
millions of liver disease patients. It advances the science and
practice of hepatology through educational conferences, training
programs, professional publications, and partnerships with
government agencies and sister societies.
View original
content:https://www.prnewswire.com/news-releases/resolution-therapeutics-announces-upcoming-presentations-at-the-american-association-for-the-study-of-liver-disease-aasld-the-liver-meeting-2024-302262983.html
SOURCE Resolution Therapeutics